| abstract |
The present invention discloses a pharmaceutical combination comprising (a) an ALK inhibitor or a pharmaceutically acceptable salt thereof and (b) at least one HDMA-2/p53 receptor inhibitor or medicinal agent, simultaneously, separately or sequentially. An acceptable salt, or at least one BRaf inhibitor or pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier; the use of the combination in the treatment of cancer; and a method of treating an individual having a proliferative disorder, It comprises administering the combination of a therapeutically effective amount. |